Pharsight

1. List of Xalkori drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8785632	PF PRISM CV	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors	Mar, 2025 (1 year, 8 months from now)
US7230098	PF PRISM CV	Aminoheteroaryl compounds as protein kinase inhibitors	Aug, 2025 (2 years from now)
US7858643	PF PRISM CV	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors	Oct, 2029 (6 years from now)
US8217057	PF PRISM CV	Polymorphs of a c-MET/HGFR inhibitor	Nov, 2029 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7825137	PF PRISM CV	Method of treating abnormal cell growth	May, 2027 (3 years from now)

Do you want to check out XALKORI patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jul 14, 2029
New Indication (I)	Jul 14, 2025

Market Authorisation Date: 26 August, 2011

Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; ...

Dosage: CAPSULE;ORAL